Place of residence determines access to interferon-beta therapy in MS;Bostadsort avgör om MS-sjuk får interferon beta-behandling: Mindre än 15 procent behandlas - Stora skillnader mellan länen

Lakartidningen

Volumn 96, Issue 49, 1999, Pages 5492-5495

  Andersson, Annelie ^a   Persson, Peter M ^b   Fredrikson, Sten ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b Apoteket AB   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG COST; DRUG UTILIZATION; ECONOMICS; HEALTH CARE DELIVERY; HUMAN; MULTIPLE SCLEROSIS; PATIENT ADVOCACY; PRACTICE GUIDELINE; PRESCRIPTION; SWEDEN;

DRUG COSTS; DRUG UTILIZATION; GUIDELINES; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PATIENT ADVOCACY; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; SWEDEN;

EID: 0033536960     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Paty DW, Ebers GC. Multiple sclerosis. Philadelphia: FA Davis Company, 1998.
2. Svenningsson A, Andersson M, Olsson T. Nya läkemedel ger lindring vid täta skov. Läkartidningen 1998; 95: 5623-30.
3. Apoteksbolaget. Apotekets centrala statistiksystem. Stockholm: Apoteksbolaget, 1999.
4. Compston A. Provision of treatment for multiple sclerosis. Lancet 1999; 353; 1710.